This research innovatively explores the early therapeutic window for MSCs in SLE, highlighting the partial mechanisms through which hUC-MSCs modulate the gut microbiota–tryptophan–AHR axis, thereby ameliorating SLE symptoms. This evidence concerns the gene AHR and systemic lupus erythematosus.